Qiagen N.V. (QGEN) Stock: Price, Forecast & Analyst Target
Qiagen N.V. (QGEN) — MoonshotScore 83/100 (Exceptional band), calculated Nov 18, 2026. Price $49.63 (+0.14%), as of the Nov 19, 2026 trading session; market cap $10.3B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 12.41× (cash as of Sep 30, 2026) · expected results Feb 3, 2027
Qiagen N.V. · QGEN · NYSE · Healthcare · Medical Diagnostics & Research
Research dated 2026-09-13: QIAGEN sells the tools that move biological material from collection and purification through molecular testing and interpretation, with consumables supplying most of its revenue. The case rests on whether its installed workflows can generate durable consumables demand while restrained sales growth, sizable debt and a shrinking cash balance leave less room for disappointment.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Qiagen (QGEN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $533M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 4.04 · Piotroski F 9
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 88 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $49.63 | |
| Change on the day | +0.14% | |
| 52-week range | $32.53–$57.82 | |
| Market capitalisation | $10.3B | — |
| Price / earnings (trailing) | 26.75 | |
| Shares traded on the day | 2.74M | |
| Beta (volatility vs the S&P 500) | 0.56 | |
| Dividends per share (last 12 months) | $2.64 | |
| Dividend yield (last 12 months) | 5.31% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For the third quarter, we expect total net sales growth of about 1% to 2% CER and adjusted diluted EPS of at least $0.62 at CER.
Roland Sackers · Statement from
For the full year, we are reaffirming our outlook for total net sales growth of about 1 to 2 percentage points at CER.
Roland Sackers · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Qiagen (QGEN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Qiagen (QGEN), and what does it report?
Short answer · as of
QIAGEN is not chiefly a laboratory-instrument vendor.
Research dated 2026-09-13.
It supplies purification kits, assay consumables, amplification products, sequencing preparation, diagnostic tests, instruments, bioinformatics and software to molecular-diagnostics and life-science customers; instruments place workflows, while recurring kit and assay use drives the larger revenue pool.
Reported revenue therefore blends demand from research laboratories and clinical testing with product categories spanning sample preparation, diagnostic solutions, genomics and nucleic-acid amplification. The consumables-heavy mix matters because testing and experiment volume can influence sales after an instrument has already been installed.
What do the latest results show for Qiagen (QGEN)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $533M.
Research dated 2026-09-13.
The latest reported period brought a rebound from the preceding period: revenue, gross profit, operating profit, net income and cash generated from operations all increased. Revenue also came in above the prevailing estimate, reversing the modest shortfall recorded in the prior report.
Across the broader annual series, sales have recovered from their trough but remain below the earlier peak, while net income has been far less stable than revenue. Management has reaffirmed modest constant-currency sales growth, framing the near-term path as gradual expansion rather than a sharp acceleration.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $547.87M Sep 30, 2026
- Latest quarter · R&D
- $53.95M Sep 30, 2026
- Latest quarter · SG&A
- $146.13M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $151.64M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $547.87M | $53.95M | $146.13M | $151.64M |
| Jun 30, 2026 | $535.04M | $50.43M | $146.77M | $132.40M |
| Mar 31, 2026 | $492.32M | $48.26M | $142.39M | $116.63M |
| Dec 31, 2025 | $540.42M | $47.23M | $153.88M | $153.90M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $548.00M Nov 4, 2026
- Latest report · revenue estimate
- $538.61M Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $548.00M | $538.61M | $0.6500 | $0.6270 |
| Aug 5, 2026 | $535.04M | $527.50M | $0.6200 | $0.5980 |
| May 6, 2026 | $492.32M | $496.15M | $0.5400 | $0.5420 |
| Feb 4, 2026 | $540.42M | $528.42M | $0.6200 | $0.6100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $533M | $130M | $0.60 (diluted) |
| Q4 FY2025 | $540M | $108M | $0.52 (diluted) |
| Q1 FY2026 | $492M | $68M | $0.33 (diluted) |
| Q2 FY2026 | $535M | $103M | $0.50 (diluted) |
What are the financial strengths and risks for Qiagen (QGEN)?
Short answer · as of
Cash and short-term investments were $830.13M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $145.63M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
QIAGEN converts operations into cash consistently, and recent operating cash flow has remained comfortably above capital spending. Profitability is also substantial across gross, operating and net measures, while the quality and distress screens do not signal immediate financial strain.
The counterweight is leverage. Debt exceeds cash and investments, leaving the company in a net-debt position, and cash has declined materially across the reported window despite positive operating cash generation. The distribution pattern has also varied sharply, so recent dividend yield should not be treated as a dependable run rate without examining the underlying payments.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $145.63M Sep 30, 2026
- Previous quarter · operating cash flow
- $200.69M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $145.63M | −$40.03M |
| Jun 30, 2026 | $200.69M | −$42.93M |
| Mar 31, 2026 | $100.63M | −$46.88M |
| Dec 31, 2025 | $188.13M | −$70.91M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Qiagen (QGEN)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-13.
QIAGEN now needs to show that the latest sequential rebound can persist without sacrificing margin or cash conversion. Watch revenue against management’s modest constant-currency outlook, gross and operating profit alongside research and selling costs, and operating cash flow after capital spending.
The balance sheet deserves equal attention: stabilization in cash and short-term investments would make the leverage position less restrictive, while another material decline would raise questions about uses of cash beyond ordinary investment. Consensus expects continuing revenue and earnings growth over the forecast horizon, making execution against that gradual path more informative than any isolated estimate beat.
What management is planning
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Qiagen compare with its peers?
Short answer
Qiagen's score ranks tied for 2nd of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
QIAGEN spans more of the molecular workflow than a focused assay maker or instrument supplier: sample stabilization and purification feed amplification, sequencing preparation, diagnostic assays and software interpretation. That breadth can deepen customer workflow exposure, but it also ties performance to a varied mix of research activity, clinical testing and consumable pull-through.
Its revenue base is dominated by consumables and related products rather than instruments alone. Investors are therefore evaluating a recurring-use model with broad workflow coverage, while current valuation measures and consensus forecasts already assume profitable, continued expansion rather than a distressed recovery.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| Qiagen (QGEN) — this page | $49.63 | $10.3B | 83 |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $176.59 Nov 19, 2026 | $10.3B | 74 5-pillar Nov 18, 2026 | |
| $151.59 Nov 19, 2026 | $16.9B | 71 5-pillar Nov 18, 2026 | |
| $61.43 Nov 18, 2026 | $11.9B | 58 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $38.60 – $52.00
- Consensus target
- $45.71
- Median target
- $46.25
Consensus record · Captured .
Measured against a quoted price of $49.63 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 69.6% Period end Sep 30, 2026
- Previous quarter · ownership
- 70.7% Prior to period end Sep 30, 2026
- Reporting holders
- 388 Period end Sep 30, 2026
- Previous quarter · holders
- 366 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Price T Rowe Associates INC /Md/ | 16,438,820 |
| Wellington Management Group Llp | 11,636,224 |
| Principal Financial Group INC | 8,395,501 |
| Vanguard Capital Management LLC | 6,256,165 |
| Blackrock, INC. | 5,807,458 |
Tracked investors
Which of the 16 named investors we follow held QGEN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported QGEN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Qiagen (QGEN)?
- UBS Maintains Neutral on Qiagen, Raises Price Target to $50
- Interpreting Qiagen (QGEN) International Revenue Trends
- Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck
What Investors Ask About Qiagen (QGEN) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why are QIAGEN Sample Technologies important to the business?
Sample Technologies place QIAGEN at the start of molecular workflows through stabilization, purification and preparation of nucleic acids. Repeated processing of biological samples supports consumables demand before downstream amplification, sequencing or diagnostic interpretation begins.
Does QIAGEN depend mainly on selling laboratory instruments?
Consumables and related products form the dominant reported revenue category. Instruments support adoption of QIAGEN workflows, but recurring kits, assays and other consumables carry greater economic weight.
What makes QIAGEN’s QuantiFERON-style immune response testing different from its research products?
Immune-response assays serve clinical testing needs such as tuberculosis and post-transplant monitoring, while research products support gene expression, genotyping and related laboratory work. QIAGEN participates in clinical and research workflows rather than relying on a narrow testing market.
Why does QIAGEN’s cash position need watching despite strong operating cash flow?
Operations have generated cash above capital spending, yet cash and short-term investments have fallen materially across the reported window and remain below total debt. Continued cash conversion must therefore be assessed alongside leverage, distributions and other uses of liquidity.
What is the QGEN stock price today?
The last price recorded for Qiagen N.V. (QGEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the QGEN price target?
The analyst consensus price target for Qiagen N.V. (QGEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does QGEN pay a dividend?
Yes. The dividend yield of Qiagen N.V. (QGEN) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 82 figures on this page — 2 from SEC filings and earnings calls, 72 from Financial Modeling Prep (FMP), 2 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com